CO COHANCE
Cohance Lifesciences Q2 2027
COCOHANCE

Cohance Lifesciences Q2 FY27 results (Jul–Sep 2026) and concall

Healthcare · Concall AI · Call held 6 Nov 2026

Management summary

  • Cohance Lifesciences delivered sequential operating recovery in Q2 FY27, with revenue growing 13% QoQ to INR 4,767 million and adjusted EBITDA margins expanding to 10%.
  • Growth was supported by a 34.5% sequential rebound in Pharma CDMO and steady 5% YoY growth in API+, though Specialty Chemicals faced headwinds from generic AgChem destocking.
  • Management reiterated expectations of YoY growth in revenue and EBITDA for H2 FY27, backed by new commercial wins and order reloads.
  • Actively addressing regulatory and CAPA matters including USFDA inspection responses and the Suryapet closure notice..

Source: Inve concall analysis and management guidance record.

Highlights

  • Revenue rose 13% sequentially to INR 4,767 million, while adjusted EBITDA expanded from INR 92 million to INR 458 million (10% margin)

  • Pharma CDMO registered a sequential revenue rebound of 34.5% QoQ driven by small molecules

  • Sapala oligo franchise continued robust momentum, growing 33.6% YoY in Q2 and 83% YoY in H1 FY27

  • Balance sheet remained cash positive with cash and liquid investments of ~INR 2.9 billion against borrowings of ~INR 2.3 billion

What they filed

Q2 FY27: revenue down 14.2%, net profit down 96.6% against the same quarter last year.

₹ Cr · quarterly
Line itemQ3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Revenue676 840 549 556 545 −19%619 −26%422 −23%477 −14%
EBITDA237 229 112 121 95 −60%99 −57%1 −99%35 −71%
Net profit153 117 46 66 29 −81%8 −93%-45 −197%2 −97%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Revenue

  • H2 FY27 Consolidated Revenue Growth Revenue · H2 FY27 · High confidence YoY growth

Profitability

  • H2 FY27 EBITDA Growth Profitability · H2 FY27 · High confidence YoY growth and sequential half-over-half improvement

Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.

Q&A highlights

0 direct, 2 evasive
Suryapet facility revenue share and impact of PCB closure order on H2 guidance Evasive
I think we are very early stages of assessing the developments that are taking place at the site... This is a development in the last 24 hours. So, attention is more on the engagement with the authorities on all the regulatory front as of now.

Management refused to quantify revenue contribution or confirm if H2 YoY growth guidance holds if the plant stays shut through Q3.

Asked by Sajal Kapoor

Suryapet historical revenue and non-GMP status clarification Evasive
We are not providing that level of guidance because we are assessing the impact and the situation at this stage. From a commercial manufacturing perspective, this is actually one of our smaller plants... This is also a plant which is a non-GMP facility.

Management deflected giving the FY26 revenue baseline for the shut unit, while clarifying that Suryapet is a smaller, non-GMP facility and closure is not expected to be permanent.

Asked by Vikash Parth

Unlock risks & concerns, Q3 FY27 watchlist, and full call analysis

You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:

  • 8 risks, concerns & management red flags
  • 4 watchlist triggers for Q3 FY27
  • +6 more guidance targets & verbatim management quotes
  • +6 more analyst Q&A exchanges & evasion checks
  • Capital allocation & full section-by-section narrative

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image